Silo Pharma, Inc. announced plans to submit an investigational new drug (IND) application for SPC-15, a novel intranasal treatment for Post-Traumatic Stress Disorder (PTSD), by the end of 2025, ...

Vancouver, Canada, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and ...

MIAMI, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Psycheceutical Bioscience, Inc ("Psycheceutical" or the "Company") (OTC: BWVI), a bioscience company dedicated to developing cutting-edge treatments for mental ...

The Food and Drug Administration declined Friday to approve an application to treat post-traumatic stress disorder using the drug midomafetamine, also known as MDMA or the street drug ecstasy, citing ...

This story discusses suicide. If you or someone you know is having thoughts of suicide, please contact the Suicide & Crisis Lifeline at 988 or 1-800-273-TALK (8255). PTSD sufferers might soon have a ...

SAN JOSE, Calif. - A San Jose-based medical company has submitted an application to begin providing patients with midomafetamine (MDMA) capsules paired with talk therapy for the treatment of ...

Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, ...

Please provide your email address to receive an email when new articles are posted on . The FDA has accepted a supplemental new drug application from Otsuka and Lundbeck for Rexulti in combination ...

WHITE OAK, MD - JULY 20: The Food and Drug Administration voted to reject therapeutic MDMA for PTSD (Photo by Sarah Silbiger/Getty Images) PTSD is a serious medical condition that affects 13 million ...

The votes were not close. The Psychopharmacologic Drugs Advisory Committee (PDAC), on the basis of the research done so far, voted 10-1 that the proposed treatment's risks outweighed its benefits and ...